The GLP-1 revolution is just beginning. Pharmaceutical companies are racing to develop even more effective medications—some showing weight loss approaching surgical levels. Here's what's in the pipeline.
The Frontrunners
Mechanism: Triple agonist—targets GLP-1, GIP, AND glucagon receptors. The first "triple G."
Why it matters: Adding glucagon receptor activation may further boost metabolism and fat burning beyond what dual agonists achieve.
Expected approval: 2026-2027 if Phase 3 confirms Phase 2 results.
Mechanism: Oral GLP-1 receptor agonist. Similar weight loss to injectable semaglutide in early trials (~15%).
Why it matters: Many people avoid GLP-1s because of needle phobia. An effective daily pill could dramatically expand access.
Expected approval: 2025-2026.
Mechanism: Combines semaglutide with amylin analog (cagrilintide). Different approach than triple agonists.
Why it matters: Amylin is a hormone that enhances satiety. Combining it with GLP-1 may provide complementary effects.
Expected approval: 2026-2027.
What This Means
For patients, this means more options, potentially better efficacy, and eventually competition that could lower prices. The obesity treatment landscape in 2030 will look very different from today.
Caveats
- Phase 2 results don't always hold up in Phase 3
- Safety signals may emerge with larger trials
- FDA approval timelines are unpredictable
- Even after approval, supply and access take time
- Jastreboff AM, et al. Retatrutide Phase 2 trial. NEJM 2023.
- Orforglipron Phase 2 data. Eli Lilly press releases.
- CagriSema Phase 2 data. Novo Nordisk clinical trial results.
- ClinicalTrials.gov ongoing Phase 3 registrations.